Lumonus launches strategic collaboration with leading global cancer center to advance radiation therapy treatment planning
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
MAYNE PHARMA EXPECTS NO MATERIAL IMPACT TO EARNINGS PROFILE FROM US PHARMACEUTICAL TARIFF PROCLAMATION
Paradigm Confirms 50% of Patients Dosed in Phase 3 OA Trial Enabling Progress Toward Interim Analysis
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
24/7 glucose monitoring now more affordable for type 2 diabetes – Ethical Strategies on behalf of Pharmaco Australia & New Zealand
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
Medicines Australia: Australia-EU agreements to benefit Australian’s health with fast tracking of Horizon Europe
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases